Objective. This study investigates the frequency at which quantitative results provide additional clinical benefit compared to qualitative results alone. A comparison between alternative urine drug screens and conventional screens including the assessment of cost-to-payer differences, accuracy of prescription compliance or polypharmacy/substance abuse was also included.
Setting and Methods. In a reference laboratory evaluation of urine specimens from across the United States, 213 urine specimens with provided prescription medication information (302 prescriptions) were analyzed by two testing algorithms: 1) conventional immunoassay screen with subsequent reflexive testing of positive results by quantitative mass spectrometry; and 2) a combined immunoassay/ qualitative mass-spectrometry screen that substantially reduced the need for subsequent testing.
Results. The qualitative screen was superior to immunoassay with reflex to mass spectrometry in confirming compliance per prescription (226/302 vs 205/302), and identifying non-prescription abuse (97 vs 71). Pharmaceutical impurities and inconsistent drug metabolite patterns were detected in only 3.8% of specimens, suggesting that quantitative results have limited benefit. The percentage difference between the conventional testing algorithm and the alternative screen was projected to be 55%, and a 2-year evaluation of test utilization as a measure of test order volume follows an exponential trend for alternative screen test orders over conventional immunoassay screens that require subsequent confirmation testing.
Introduction
Chronic, non-cancer pain is a leading reason for patients to visit their health care provider in the United States, consistent with high rates of prescription drug use, abuse, and incidence of overdose [1, 2] . Opioid prescriptions have increased more than 100% in the United States since the late 1990s [3] when laws and regulations were changed to permit more broad use [4] .
Opioids account for a majority of deaths due to prescription drug overdose [2] . Measures to mitigate prescription drug abuse and overdose against a backdrop of an increasing number of pain-related prescriptions has led to published guidelines requiring implementation of prescription compliance and drug abuse monitoring programs that include routine urine drug testing at a frequency dictated in large part by risk factor assessment for the individual patient [5] .
Historically, clinical toxicology laboratories have used a forensic toxicology workflow in diverse settings from poisonings to pain management compliance testing. Assays and testing workflows were based on screening drug classes by immunoassay (IA) and subsequent confirmation/quantitation of positive screen results by mass spectrometry (MS)-i.e., screen with reflex to confirmation workflow. While point of collection IAs have valuable clinical utility by way of real-time patient interaction, conventional IA screens are far from ideal for monitoring prescription compliance because: 1) drugs and drug metabolites are expected to be present, leading to a majority of samples being reflexed to confirmationthereby increasing cost, lab burden, and turnaround time [6, 7] ; 2) in general, IA screens have poorer specificity within drug classes [8] ; 3) by design, IAs have limited sensitivity as cutoff concentrations are more suited for workplace testing (e.g., opioids) to avoid false positives yet have a high rate of false negative results for some drug classes (e.g., benzodiazepines) [9] ; 4) many drugdetection IAs have high rates of false positivity (e.g., amphetamines) [10] ; and 5) several drugs utilized in pain management are not commonly included in drug screening IA panels (e.g., fentanyl and tramadol).
Ramifications of patient non-compliance and, similarly, drug abuse include patient consultation (71.6%), repeat testing (41.2%), or discontinuation of therapy prescription (18.6%) [11] . When non-compliance or drug abuse allegations are incorrect, i.e., false negatives or false positives, outcomes include an increase in patient/clinician consultation time, testing costs, adverse patient/clinician relationships, and poor management of the patient's pain.
Quantitative and qualitative multi-analyte panels are emerging as alternative urine drug screens to replace conventional testing in light of guidelines encouraging compliance monitoring, reimbursement structure modifications, and efforts to improve test utilization. Alternative urine drug screens to date are based on MS or combined MS/IA and demonstrate value in streamlined reporting, decreased numbers of false positives, parent drug and metabolite profiling, and faster turnaround times [7, [12] [13] [14] . Furthermore, alternative urine drug panels can be customized to best serve a specific patient population while aligning with restructuring urine drug testing reimbursement in an effort to reduce cost and fraud while also encouraging appropriate test utilization.
Studies comparing testing costs and accuracy of prescription compliance or drug abuse between conventional and alternative screening methods are lacking. Also, quantitation and confirmation are often incorrectly tied together in the minds of ordering clinicians and laboratories that perpetuates the wide standing belief that quantitation is essential for urine drug compliance testing interpretation. This study compares a qualitative MS/IA-based alternative screen [7] to a conventional workflow of an IA screen reflexed to quantitative mass spectrometry (MS), and assesses variations in cost, ability to accurately determine compliance and utility of quantitative results.
Methods
Urine specimens (N ¼ 213) from patients throughout the United States were submitted to ARUP Laboratories (CLIA-accredited reference laboratory, Salt Lake City, Utah) to be tested for prescription compliance and drugs of abuse by the alternative urine drug screen method. Subsequent to this analysis, and within the stability requirements of the urine specimens, these same specimens were analyzed by a conventional immunoassay screen where positive results were further tested by quantitative mass spectrometry ( Figure 1 , Table 1 ).
Alternative Screen Method
The alternative screen method is a pain management panel that combines high resolution time-of-flight mass spectrometry (TOF-MS) to detect 37 drugs/metabolites (cutoff, ng/mL): buprenorphine (5) . A complete description of method parameters was previously described [7] . Briefly, one urine aliquot was diluted in pH 9 bicarbonate buffer containing three deuterated internal standards followed by supported liquid extraction and analyzed using a 7.5 minute gradient on a 1260 liquid chromatograph with a Poroshell C18 columns, 2.1 Â 100-mm, 2.7-mm particle size (part number 695775-902; Agilent Technologies) coupled to an Agilent 6230 time-of-flight mass spectrometer in positive ion mode. Drug-negative urine was used to prepare positive and negative quality control material fortified to cutoff concentrations per analyte tested. Analyte responses above the cutoff concentration in patient specimens were resulted as positive. A second aliquot of the primary urine specimen was used for the immunoassay portion of the testing as per manufacturer's directions.
Conventional Method
The conventional IA screen with reflex to MS testing workflow consisted of analysis by a Beckman AU5810 instrument with Siemens Syva Emit II Plus homogeneous enzyme immunoassays (cutoff, ng/mL): amphetamines (300), barbiturates (200) propoxyphene, and PCP, as previously published [7] . Briefly, analytes are obtained by using solid-phase extraction of the patient specimen that contains deuterated internal standards. Barbiturates and cocaine metabolite were detected by GC-MS (Agilent 6890N/ 5973; Agilent Technologies, Santa Clara, CA), after derivatization. Amphetamines (including MDMA), benzodiazepines, THCA (a cannabinoid metabolite), methadone, opiates (including oxycodone), PCP, and propoxyphene, 
Prescription Assessment
Physicians provided current prescription information with the specimens for interpretation of compliance and substance abuse. Prescriptions not covered by immunoassays or the alternative mass spectrometry method were not included in the analysis. Compliance or abuse based on immunoassay results were evaluated per drug class while mass spectrometry methods allowed for evaluation based on the presence of parent drug and primary metabolites. Analyte responses for parent drugs and metabolites that were not included in the patient prescription history were counted as events of substance abuse. There were 302 total prescriptions provided for the 213 urine specimens tested, representing the following drug classes: opiates/opioids (228), sedatives/hypnotics (66), and stimulants (8) . The LC-TOF/MS and the LC-MS/MS methods provide definitive results as they provide high resolution data or fragmentation data, respectively, that do not require subsequent confirmatory testing. Therefore, because the LC-TOF/MS method was used for all 213 specimens and the LC-MS/MS method was used to confirm the IA positive drug classes, the specimens did not require additional testing by a third method. Protocols for utilizing these data were approved by the University of Utah Institutional Review Board (#00007275). Value in Alternative Screen Utilization Table 1 Drug classes, parent drugs, and primary metabolites detected by the alternative and conventional testing algorithms 
Results
Overall positivity and the percentage of those positive results inconsistent with supplied medication information, respectively, for common drug classes were as follows: opioids (72.8%, 26%), cannabinoids (12.2%, 100%), benzodiazepines (24.4%, 37%), and amphetamines (7.5%, 44%).
In comparing the alternative screen against the conventional method to evaluate prescription compliance and drug abuse detection, the alternative screen was superior to screen with reflex to quantitation in confirming compliance per prescription (226/302 vs 205/302), as well as in identifying non-prescription substance abuse (97 vs 71) (Figure 1 ). While overall compliance and detection of substance abuse was superior in the alternative screen, we identified 12 instances (3.8% of specimens) ( Figure 1 , Table 1 ) where quantitation was useful in distinguishing drug use from pharmaceutical impurities or to evaluate parent compound concentrations when metabolites were absent, indicative of medication addition directly to the specimen. As an example, one specimen in the study from an individual prescribed hydrocodone was positive for hydrocodone and codeine, which can be consistent with compliance to hydrocodone with codeine present as a pharmaceutical impurity, as tolerances for pharmaceutical preparations of hydrocodone allow for 0.15% codeine. However, quantitative testing of this sample indicated polypharmacy rather than impurity as the codeine concentration was 53% that of hydrocodone. Our data set also Table 1 Continued Value in Alternative Screen Utilization includes 26 specimens positive for THC and 12 positive for methadone (urine detection window 1-45 days and 1-14 days, respectively). Because of the prolonged urine detection of these compounds, quantitation may be beneficial in follow up testing when clinicians have advised cessation yet retesting occurs within the elimination window [16] .
As a measure of clinical utility and adoption of the alternative workflow, we plotted test ordering volumes as a function of time since alternative MS-based testing was made available at our institution. Clinicians were made aware of the alternative testing algorithm by direct communication and marketing as is done commonly with new test offerings. Data demonstrate a substantial adoption of the alternative workflow based on test order volumes towards alternative screen workflow (a growth rate average of around 250% per month) while during that same time, conventional workflow testing volumes did not increase in volume (Figure 2 ). Of the 213 urine specimens analyzed in our data set, IA false positives were attributed to opiates and amphetamines/MDMA, whereas false negatives were mainly associated with benzodiazepines, opiates, and oxycodone. To further evaluate rates of IA false positivity rates, we performed a retrospective analysis of urine specimens tested at our facility that were positive by IA but failed to confirm by MS. IAs for barbiturates, THC, cocaine, methadone, carisoprodol, and ethyl-glucuronide had false positivity rates of less than 2% and tramadol $5% (Table 2) .
On average, specimens were positive by IA for more than one drug class, leading to a confirmation rate of 1.34 per specimen (Figure 1 ). This confirmation rate led to a calculated total normalized cost of 342.96 for the 213 specimens tested by the conventional algorithm where the normalized IA cost was 0.62 per specimen and the LC-MS/MS quantitation cost was 0.74 per specimen. The alternative qualitative method total normalized cost for all 213 specimens was 221.88, which includes the selective quantitation of 3.8% of samples at a cost of 0.72 each. Therefore, the percentage difference between the two testing algorithms is 55% in favor of the alternative screen. We also evaluated how cost would be affected by the decision to perform universal secondary conformational analysis of positive results from the IA portion of the alternative screen despite their low false positivity rate ( Figure 1 , Universal IA Confirmation). Of the 213 specimens tested, 107 positive results by the IA portion of the alternative screen were observed. The cost associated with performing universal confirmation testing on these 107 results as opposed to selective confirmation of the 12 specimens where there would be an anticipated clinical benefit, is 33% higher (i.e., 1.37 vs 1.03) yet would not likely add any clinical benefit compared to selective confirmatory testing (Table 3) .
Discussion
The alternative screen was superior to IA screen alone or screen with reflex to quantitation in confirming compliance per prescription. This is largely explained by increased detection of true positives in the alternative screen as more drugs are screened by this method and the elimination of false negative results by the IA method that are not reflexed to confirmation. The former reason may be attributed in part to the varied backgrounds and understanding of clinicians ordering pain management testing with regards to which drugs are actually tested for in conventional immunoassay screens [16] . Also, lab test ordering interfaces tend to have limited information describing cross-reactivity profiles within drug classes. For instance, some clinicians may be surprised to know that an opiate/oxycodone IA does not detect many semi-synthetic opioids. In this scenario, if a drug is prescribed but not tested for in the drug panel, the patient may be thought to be non-compliant. Interferences, high assay cutoffs, and dilute urine specimens are all potential causes of false negative IA results. MS-based methods typically have better analytical sensitivity than IAs, primarily due to more rigorous sample preparation, in-line chromatographic separation, and the ability to report the detection of compounds to a relatively lower concentration. However, our data indicate that a small number of false negative results in the alternative screen were attributed to missed benzodiazepine detection. Because benzodiazepines are highly glucuronidated in urine, the alternative screen, which measured only non-glucuronidated (i.e., free) drug at the time of this testing, had a sensitivity disadvantage when compared to the quantitative LC-MS/MS method which included a more laborious enzymatic hydrolysis of glucuronidated metabolites (i.e., total drug). Many of these false negatives were resolvable in the data set by reviewing and reporting data below the originally established cutoff for oxazepam, lorazepam, and alprazolam.
Compared to quantitative MS methods, qualitative MSbased screens have the added benefit of: 1) utilizing a minimal number of internal standards to establish positivity cutoffs, whereas quantitative methods typically employ internal isotopically labeled standards for each analyte tested; and 2) reporting results to a well characterized cutoff for each compound to mitigate reporting false negative results.
Maximal specificity in resolving parent drugs and metabolites as well as reduced turnaround time in comparison to conventional workflows are two reasons for the adoption of this alternative testing workflow. Our previous data demonstrate a significant turnaround time advantage for the alternative screen versus conventional testing algorithms for both in-lab (29.6 vs 61.8 hours, respectively) and total (60.6 vs 137.1 hours, respectively) turnaround time [7] . In addition to observing increased volume for alternative screening, we have detected an increased number of clinicians providing prescription information for the result to be fully interpreted by a toxicologist associated with the performing laboratory. This correlates with the two populations of clinicians likely ordering these tests, i.e., those who practice pain management secondarily and feel ill-prepared to adequately interpret results, or those who manage a larger patient load and want to maintain efficiency without compromising quality. While point of collection testing (i.e., at the patient) enables clinicians to have real-time communication with patients, a 2012 survey of pain clinicians indicated 65.7% utilize conventional IAs near patient (i.e., at their institution or clinic), and outside labs for confirmatory/quantitative testing, with an additional 27.5% who send both qualitative and quantitative testing to an outside lab [11] . Under these circumstances, significant reduction in turnaround time can be achieved by having an alternative screening approach, especially in the former example where turnaround time is prolonged by having the testing done in multiple locations.
We recently demonstrated how the alternative screen employed in this current study, results in faster turnaround times than conventional IA reflexed to MS even when performed at the same location [7] .
Definitive Method Approaches
Targeted and untargeted approaches to urine drug screening by MS were initially developed as forensic tools to investigate drug abuse, overdose, or poisonings [17, 18] . In the setting of pain management and drug monitoring, quantitative and qualitative targeted screens are developed as stand-alone MS methods (e.g., LC-MS/MS [12] , or LC-TOF/MS [13] ) or as a combination of high performing IAs and high resolution MS [7] , as was evaluated in this current study. These varied approaches demonstrate how quantitative and qualitative approaches can be used as well as the appropriateness of including IAs with acceptable performance as part of an alternative screen. It is widely accepted that urine drug IAs which yield positive results are presumptive and require confirmation by an independent method such as MS. While this holds true for IAs with poor resolution within drug classes (e.g., opioids and benzodiazepines), or that have a high rate of false positives or false negatives due to off target cross reactivity (e.g., amphetamine and MDMA), there are certain IAs that have adequate specificity and sensitivity to be used in a definitive manner.
Manufacturer product inserts show that these same IAs also have favorably low false negative rates. Therefore, high performing IAs in urine drug testing can be utilized in a definitive manner, where positive results that do not support clinical findings can be confirmed by a secondary method (e.g., mass spectrometry) on a case by While conventional analyzer-based and point of carebased IAs offer rapid analysis at a low initial cost, in a pain management setting where specimens are expected to be positive for prescribed drugs and their metabolites, preliminary IA results offer little value as the positive specimens will ultimately require follow-up testing for accurate interpretation. Decision analysis models, also called decision trees, are useful models to illustrate testing strategies and for cost comparison. Using data obtained in this study we found a potential cost difference of 55% in favor of the alternative screening algorithm even when selective quantitation was carried out (Figure 1 ).
Conclusions
Due to poor analyte specificity within a drug class, it is nearly impossible to resolve compliance, polypharmacy, or abuse of a non-prescribed drug based on immunoassay results alone, resulting in obligatory MS-based confirmatory testing, and a wide standing belief that quantitation is essential for urine drug compliance testing.
Quantitative and qualitative definitive screens in pain management and drugs of abuse testing are an attempt to offer a less expensive, faster, and comprehensive evaluation of patient medication compliance and drug abuse. Our study of a combined IA/qualitative-MSbased alternative screen demonstrates increased accuracy of compliance and drug abuse determination, as well as a substantial cost benefit, when compared to a conventional IA screen reflexed to quantitation and contests a wide standing belief that quantitation is essential for urine drug compliance testing. While drugs with extensive metabolism and glucuronidation are challenging to detect without hydrolysis, high-sensitivity qualitative MS screens have additional utility in reporting results to the LOD to mitigate reporting false negative results. Infrequently, subsequent quantitation after an alternative screen may provide additional insight for interpretation of analyte concentrations and ratios. High performing IAs have utility in alternative screens and can be coupled with MS to offer broad drug detection; adequate reimbursement; streamlined, cost-efficient, and effective monitoring of drug compliance; or detection of drug abuse in a pain management setting.
